Company / Free Cash Flow
Summit Therapeutics Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$323.6M
FY2025
5-year range
-$323.6M / -$72.9M
FY2021-FY2025
Trend
-127.5%
vs FY2024
Sector context
#173 of 194
Health Care
What the data says
Summit Therapeutics Inc.'s free cash flow of -$324M is lower than 89% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 3 consecutive years, from -$73M in FY2022 to -$324M in FY2025.
Based on SEC 10-K filings.
-$324M in FY2025.
Declined from -$77M to -$324M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 194This company -$323.6M Sector average $470.6M
▼
-168.8% below sector average
Key checks
Key Insights
- Summit Therapeutics Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2025, free cash flow decreased 127.5% year-over-year.
- Ranks #173 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$323.6M | -127.5% |
| FY2024 | -$142.2M | -85.0% |
| FY2023 | -$76.9M | -5.5% |
| FY2022 | -$72.9M | +0.0% |
| FY2021 | -$72.9M | -50.2% |
| FY2020 | -$48.5M | -131.5% |
| FY2019 | -$21.0M | +40.6% |
| FY2018 | -$35.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026